What is UltraMIST therapy and how should it be applied for the treatment of chronic wounds such as diabetic foot ulcers, pressure injuries, and venous or arterial ulcers?

UltraMIST Therapy Should Not Be Used for Chronic Wound Management

Based on the most recent and highest-quality evidence, UltraMIST therapy (a form of low-frequency, noncontact ultrasound) should not be used for the treatment of chronic wounds including diabetic foot ulcers, pressure injuries, and venous or arterial ulcers. The International Working Group on the Diabetic Foot (IWGDF) 2023 guidelines provide a strong recommendation against using physical therapy interventions, including ultrasound, for wound healing in diabetes-related foot ulcers 1.

Guideline-Based Recommendation

The IWGDF 2023 update explicitly states: "Do not use any interventions reported in the field of physical therapies for wound healing in the management of diabetes-related foot ulcers" (Strong recommendation; Low quality evidence) 1. This recommendation was reinforced in the 2020 IWGDF guidelines, which specifically stated: "Do not use agents reported to have an effect on wound healing through alteration of the physical environment including through the use of electricity, magnetism, ultrasound, and shockwaves in preference to best standard of care" (Strong recommendation; Low quality evidence) 2.

Why This Recommendation Matters

Strength of Evidence Against Use

• The 2023 IWGDF guidelines represent a complete re-evaluation of all wound healing interventions using only randomized controlled trials and updated GRADE methodology 1
• Despite earlier observational studies suggesting benefit, the systematic review found insufficient high-quality evidence to support ultrasound therapy for chronic wounds 1
• The strong recommendation against physical therapies reflects the guideline committee's assessment that potential harms, costs, and resource utilization outweigh any uncertain benefits 1

Limited Research Evidence

While older retrospective and observational studies from 2006-2008 suggested potential benefits of MIST therapy (showing 53-69% healing rates in small case series), these studies had significant methodological limitations 3, 4:

• No blinded comparisons to standard care alone
• Small sample sizes without adequate controls
• Retrospective design prone to selection bias 3, 4

A 2008 systematic review concluded there was "insufficient evidence to determine whether ultrasonic mist therapy effectively debrides necrotic tissue in chronic wound beds" 5.

Physical Characteristics Limit Effectiveness

Laboratory characterization of the MIST device revealed a critical limitation: due to acoustic impedance mismatch between air and soft tissue, the device delivers only 0.1% of its incident ultrasound intensity into the wound site 6. This physical constraint raises fundamental questions about the biological plausibility of therapeutic effects.

What Should Be Used Instead

Evidence-Based Standard Care for Diabetic Foot Ulcers

• Sharp debridement of slough, necrotic tissue, and surrounding callus (Strong recommendation) 2
• Appropriate dressings selected based on exudate control, comfort, and cost (Strong recommendation) 2
• Offloading to minimize trauma to the ulcer site 7
• Infection management when present 7
• Revascularization if ischemia is present and feasible 8

Adjunctive Therapies to Consider When Standard Care Fails

For diabetic foot ulcers that fail to respond to standard care, the IWGDF suggests considering (all conditional recommendations with low-to-moderate evidence):

• Autologous leucocyte, platelet, and fibrin patch (Conditional; Moderate quality evidence) - the only intervention with moderate-quality evidence 1
• Placental-derived products as adjunctive therapy (Conditional; Low quality evidence) 1
• Negative pressure wound therapy for post-surgical wounds only, not for non-surgical ulcers (Conditional; Low quality evidence) 1
• Hyperbaric oxygen therapy for non-healing ischemic ulcers where resources exist (Conditional; Low quality evidence) 2

Critical Pitfalls to Avoid

• Do not use ultrasound therapy as a substitute for proven standard wound care interventions 1
• Do not delay revascularization in ischemic wounds while pursuing unproven physical therapies 8
• Do not use topical oxygen therapy - this received a specific recommendation against use in the 2020 guidelines 2
• Avoid resource-intensive unproven therapies that divert healthcare dollars from evidence-based interventions 1

FDA-Labeled Product Information

The FDA-approved UltraMIST product appears to be labeled as an antibacterial topical spray 9, with warnings for external use only and to avoid contact with eyes and broken/irritated skin 9. This labeling does not support its use as a wound healing therapy and suggests it functions primarily as a topical antimicrobial agent rather than a therapeutic ultrasound device.

Bottom Line

Prioritizing patient outcomes of morbidity, mortality, and quality of life, clinicians should not use UltraMIST or other ultrasound-based therapies for chronic wound management. Resources should instead be directed toward proven interventions including sharp debridement, appropriate offloading, infection control, revascularization when indicated, and evidence-based adjunctive therapies when standard care fails 1, 2.